@article {701,
	title = {Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers},
	journal = {Exp Hematol},
	volume = {24},
	year = {1996},
	note = {Huhn, R D Yurkow, E J Tushinski, R Clarke, L Sturgill, M G Hoffman, R Sheay, W Cody, R Philipp, C Resta, D George, M Comparative Study Research Support, Non-U.S. Gov{\textquoteright}t United states Experimental hematology Exp Hematol. 1996 Jun;24(7):839-47.},
	month = {Jun},
	pages = {839 - 47},
	edition = {35217},
	abstract = {To identify a precisely timed and safe protocol for progenitor cell mobilization, we studied the effects of rhIL-3 and rhG-CSF administration to normal volunteers. rhG-CSF 5 micrograms/kg/d was administered subcutaneously (s.c.) for 7 consecutive days either alone or preceded by rhIL-3 5 micrograms/kg/d s.c. for 4 consecutive days in sequential or partially overlapping schedules. The combined cytokines were well-tolerated--adverse effects were similar to those of the individual agents. Total white blood cell (WBC) and neutrophil counts rose briskly in response to rhG-CSF, and peak mean values were similar between treatment cohorts. Mean platelet counts were modestly elevated during rhG-CSF treatment only in the cohorts receiving rhIL-3 and rhG-CSF. Mean circulating CD34+ cells peaked on day 5 in the rhG-CSF group (38.9+/-14.3/microliter), day 6 in the sequential rhIL-3/rhG-CSF group (56.4+/-12.4/microliter), and day 6 in the partial overlap group (46.1+/-10.9/microliter). On day 3, mean CD34+ cell counts of the subjects who received sequential treatment were markedly higher than observed in the other groups (p<0.05) and were estimated to have been sufficient for collection of adequate grafts by single 10-L leukapheresis procedures in 60\% of subjects. Circulating clonogenic cells (CFU-GM and/or BFU-E) were substantially higher in the sequential group than the rhG-CSF group on days 3-6 but were only minimally elevated above baseline in the partial overlap group. The numbers of circulating CD34+/Lin-/Thy-1+ cells (putative stem cells) were increased substantially, especially in the sequential group. On the basis of this pilot trial, we conclude that priming with rhIL-3 is a safe and well-tolerated method for enhancing the mobilization of human blood progenitors and stem cells by rhG-CSF.},
	keywords = {Adult, Antigens, CD34 / analysis, Antigens, Thy-1 / analysis, Colony-Forming Units Assay, Drug Synergism, Female, Filgrastim, Granulocyte Colony-Stimulating Factor / *pharmacology, Hematopoietic Stem Cells / *drug effects, Humans, Interleukin-3 / *pharmacology, Leukapheresis, Leukocyte Count / drug effects, Male, Recombinant Proteins / pharmacology, Safety},
	issn = {0301-472X (Print) 0301-472X (Linking)},
	author = {Huhn,R. D. and Yurkow,E. J. and Tushinski,R. and Clarke,L. and Sturgill,M. G. and Hoffman,R. and Sheay,W. and Cody,R. and Philipp,C. and Resta,D. and George,M.}
}
